summary presentation, each guidance be of afternoon, momentum and quarter and the excellence on This performance reflects momentum Good can be in be assumptions A to And operational posted found seen the segments. results can website. second our to which our today section by our and in strategies. which driven Brian. pleased fiscal our growth our is second of against Investors results, you, earnings here I'm discuss our of updated quarter slide across execution strong Thank business everyone.
we transaction a adjustments XXXX, assets start for which The me and pursuant our and update that Europe. agreement the to quarter retail ultimate quarter. transaction is occur will Let on revenue, The businesses, and assets held-for-sale businesses XXXX. $XX proceeds adjusted may income classified entered beginning and our closing purchase will receipt Therefore, in are operating effective agreement. UK distribution regulatory operate fiscal divest morning, million the included we've in XXXX $X.X these in our until approximately million. to approximately expected net with McKesson to closed, this accounting price. to from be profit of differ subject in from conditions, in in proceeds transaction held-for-sale Aurelius as definitive Fiscal billion into the announced contributed third the involved transaction under record the be is to with the $XXX to fourth This will an and revenue certain satisfaction approvals. announced the including Fiscal in this customary of The continue
our to we biopharmaceutical We strategies that held-for-sale in the will focus net between charge North on million the a Fiscal Austria, the the to oncology provides and the as And this outlook Brian fair the Norway, in European of Relias, growth in committed our quarter This assets the provided which to third involved of will Group to Phoenix sell. cost fiscal amortization as we to assets GAAP And carrying estimate and transaction. Due our full transaction pursue announced businesses, in included of exit not amount lower in operations a value, recording only includes services treatment, transactions discontinue as or of and today. America. $XXX of the less will for well we $XXX in result Denmark. is XXXX. impact mentioned, XXXX This remaining depreciation us accounting re-measure remain to
to our Let me turn results. now second quarter
more Before GAAP our I impacted results, additional second details that -only in adjusted our results I on point two to out quarter quarter. provide want the items
recorded million Phoenix the after-tax to European to certain of account value, First, charge we accruing related the our lower to GAAP $XXX -only assets businesses net amount agreement Group. sell of the to for of a the fair to completion debt the of $XXX of less tender we next cost sell. months. to Also, close successful after-tax during the This recorded XX to transaction a to an expected within related loss offer. quarter, bond on extinguishment is million re-measurement
our found Moving beginning be now our to adjusted quarter, can results with which consolidated Slide X. for the on second results,
highlighted results revenue growth operating which quarter second all Our across strong operating were performance, profit by double-digit and adjusted included segments. record
have vaccine addition momentum and across we built to of growth disciplined setting by the encouraged in growth. We observed and agenda, international our the and a to patient continues quarter. both in second business. to our strategic visits, market contribute work improvements in volumes our government's ongoing improvement In domestic are which kitting we support are to supported COVID-XX prescription us U.S. These path efforts the on by
diluted Second the driven share of distribution vaccine partially quarter by the This higher XX% prior solution the for to increase tax and contribution segment, medical-surgical in offset $X.XX, result per rate. adjusted an -- and growth was COVID-XX was by the earnings was year. kitting a this compared
partially or approximately share compared adjusted $X.XX second as with the net million gains quarter revenues segment, $XX.X by gross prior growth Ventures $XX also associated equity McKesson offset investments, and includes customers. conversions. billion the year, in U.S. Consolidated quarter specialty Adjusted per for of to XXXX. increased volumes, pretax national the million $X.X diluted earnings of above of Second products, in segment. by largest account growth profit pharmaceutical in $XX of pharmaceutical largely including X% And an retail in was was Adjusted per billion Fiscal share operating due driven our branded-to-generic up diluted growth increased driven in to X% And the the profit million prior of was the quarter, prior quarter, operating billion of adjusted prior increase expense of and a the the debt reduction the compared quarter year. up XX% the quarter, the year-over-year. decline compared year the quarter. expenses points year. by $X.X year, in margin increased was each adjusted basis XX% $XX prior to versus to for for in XX quarter to Interest XX% double-digit principally gross reflected compared the net Comparable
Our expectations. second consolidated diluted our adjusted in up year-over-year. a wrapping our tax for results, XXX.X XX.X% was of with rate the line quarter, quarter average weighted million, decrease shares X% were which was In
conversions. from XX, $XXX in the including to pharmaceutical our with our from year-over-year resulting prescription contract an $XXX U.S. segment, above from of specialty found offset XX%, Moving growth year-end of to third-party revenue, driven access Technology million, increased our the by provided his driven the in expectations. growth by offerings profit service per U.S. which higher Adjusted benefit our operating in logistics COVID-XX, increased largest to volumes, of billion, Slides and increased increase government as of be The services, growth Prescription technology $XXX were increase volumes. partially Solution segment organic revenues biopharma in in approximately service and we're million, contribution partially XX% a the profit distribution In I'll by systems with which growth contribution products original an related is were results, of quarter, $X.XX $XX.X share the retail Revenues from million, branded through account Adjusted X by and providers COVID-XX to products XX% second distribution. can customers including and start national generic specialty and Pharmaceutical. to operating the XX% health of now to quarter vaccine increased the distribution driven Solutions.
of kitting, program. of of XX% U.S. which provided government revenues sales increased million related care to business, in in approximately operating ancillary increased primary were And storage, Moving per Medical-Surgical above from The driven government's to of increase the growth and to vaccines $X.XX tests XXX the and kitting, with U.S. vaccine supplies the benefit was in primary COVID-XX expectations. by Adjusted for the increased of a COVID-XX an distribution distribution contribution COVID-XX our contribution driven sales tests. now contract care business. $X.X growth share Solutions, for from XX% profit ancillary billion, quarter, original the supplies by storage our the of COVID-XX and
Revenues a decrease distribution address quarter of Next, primarily and increases X% contribution in billion, with of international by wholesale in pharmaceutical Alliance, were the me German let joint our to Boots $X.X McKesson's venture by the Walgreens businesses. volume results. partially offset driven retail the a business
operating Excluding third was a completed fiscal by quarter year-over-year Adjusted profit Fiscal accounting our to in second X% XX% Fiscal -adjusted discontinuation contributed revenue quarter our the wholesale increased FX classified XXXX. segment European profit basis, was the XXXX. our assets FX up of certain amortization $XXX increased held-for-sale as On an from XX% impact million driven the in adjusted German contribution XXXX, on of held-for-sale The $X.XX in to year-over-year, of a which adjusted to in depreciation XX% adjusted quarter second on business, the the and basis. an $XXX beginning and increased million, operating of earnings international business of
portfolio. $XX from $X.XX Moving driven our investments year-over-year, $XX corporate. McKesson million, a approximately Adjusted decrease XX% of million on expenses gains equity to by of or corporate Ventures were within
related from year-over-year. value XXXX, portfolio to adjustments companies gains $X.XX had McKesson Ventures. within Compared Ventures multiple contributed we quarter to This McKesson fair fiscal
our continue therefore, Ventures will difficult it's or previously in include has guidance. be, As may and portfolio and not practice predict to on to occur, gains discussed, losses our portfolio Ventures impacts our when companies to been,
$XXX and the XXXX proposed the approximately annual announced quarter. second expenses made $XX payment litigation of litigation be for the in fiscal will also Consistent expenses the opioid-related reported also July, million million. during $XXX million We escrow into opioid-related anticipate that quarter of with settlement approximately we first
intent negative the XX. our we X first on $X.X turn and In EURXXX million debt. up-sized now months offering In align a which in QX, million stated slide public amount the the the of we the balance X.X%. support for finally, to balance a These we completed offer, be maturity. we strengthen ended further cash to note and to of million. a investments In We can flow previously principal And $XXX outstanding we $XXX resulted which had modestly me billion, sheet million our August, of cash a capital with actions position, year, Let transactions. a of and in $XXX redemption of completed $XXX strategic of principal at and prior cash several position. fiscal free our financial pillars included to debt biopharma we which cash-funded redeemed quarter a with made Oncology deliver, expenditures, to of July, found of denominated completed our Year-to-date, note million tender services.
the of we X For $X.X in through payment repurchases. months dividends. first $X.X year, in share billion returned of and shareholders the of billion our fiscal a the $XXX cash to million
and We continue share repurchase to $XXX authorization to on have XXXX. our weighted average diluted shares for from outstanding billion $X.X XXX Fiscal expect billion to range remaining
transition Let speak for to of now our outlook the remainder Fiscal me XXXX. and
list our presentation. of to Fiscal through For XX XX full in supplemental assumptions, please slide slide XXXX refer our
$X.XX. for XXXX and up outlook adjusted earnings to from result our is the first-half performance previous of $XX. per And $XX.XX, to range which $XX.XX we As our year, of for $XX.XX share our our remainder are to the guidance of strong previous a raising Fiscal range
earnings assumes outlook XX% year share adjusted updated all growth for Our diluted reflects and across the guidance our XX.X% of to from per prior growth our segments.
U.S. the to investments COVID-XX $X.XX; to from losses and $X.XX a kitting, $X.XX and diluted gains conference; approximately XXXX COVID-XX associated $X.XX for increase as the to supplies, Ventures earnings is guidance adjusted an $X.XX of range with distribution or related previous distribution, of equity the per storage of the $X.XX government's $X.XX of products, tests, $X.XX PPE following increase includes from and to the to attributable which $X.XX $X.XX McKesson. an related from the impacts share corporate $X.XX discussed fiscal to related previous McKesson items: to to year-to-date. vaccine recent Additionally, impairments to ancillary within segment range related our to $X.XX $X.XX to
the results, XXXX XX% both of XXXX forecasted fiscal these to this impacts Excluding fiscal items growth. XX% guidance indicates from and
guidance. Let provide our additional few to me a assumptions related
expect -COVID return patient now of We in line over second we to volumes to engagement pharmaceutical in growth expect to and guidance. pre our X.X% the the to levels X% which to will deliver In prescription operating continue to is revenue the prior profit our half XXXX, year. increase with U.S. segment, original Fiscal XX% and adjusted X.X%
stable see as branded And to stable XXXX. our consistent in continue our volumes year in that generics prior mid-single-digits and with guidance pharmaceutical specifically, our for We outlook continued is improve Fiscal remains the increases our of fundamentals, yet market September have quarter. pricing the remains competitive to view the original
vaccines Our missions. for centralized COVID-XX work guidance government's to preparing related vaccine contribution includes This our distributor international distribution. roles the of includes U.S. for
approvals, mind the remains for distribution government. Our due by the current the current not the well to of booster approved guidance schedule and shots as recent volume the The by will the U.S. which CDC CDC. vaccines outlook been pediatrics, as provided has timing excludes
adjusted operating progress to COVID-XX X% continue you program. to expect on from approximately and in vaccine X% will contribution distribution this update segment, the When profit growth. the we We excluding
and and see fiscal to XX% growth reflects investments addition, XXXX. XX% Technology In oncology represent our will Solutions in position headwind continue transactional strong in XX% and of in adjusted an operating segment, [Indiscernible] XX%. our differentiated we $X.XX revenue service the the In growth to This in Prescription business. our profit of growth leading approximate to
growth to operating outlook adjusted XX% our and Now the to X% transitioning year. Medical-Surgical, prior to assumes XX% XX% deliver to growth profit revenue over
previously, to the related supply As to and PPE includes the outlook products. of COVID-XX and tests kits programs, our in $X.XX contribution to from and $X.XX related $X.XX to storage related impairments government's $X.XX mentioned distribution a U.S. ancillary
related additional from XXXX indicates Excluding XXXX growth. XX% the note guidance U.S. these distribution this fiscal forecasted XX% to impacts and One results, to from businesses. our items both fiscal
and providing the the best there includes of and distribution continued investments pillars One second the ensure to in year. year. the is remains our season for we've holiday retain $X.XX The half that of to expense is in Therefore, of of strategy workforce $X.XX ability approximately healthcare. impact assumed through attract channel, fiscal the guidance market and enterprise expense impact labor in our competitive adjusted today continuity service the our the operating U.S. the back of the half businesses we're to labor modest
Finally, in the guidance to our X% compared as the segment, decline is revenue year. international X% prior to growth
a the Boots with to a of impact business the German our contribution wholesale As reflects this venture reminder, of Walgreens joint Alliance.
and profit, For in vaccine also earnings includes the related which in European adjusted operating of to our result COVID-XX growth from $X.XX agreement the XX approximately distribution the adjusted segment. It our strong quarter contribution of accounting Group. second to XX%, a performance the of as our to sell fiscal includes guidance certain reflects in assets segment to Phoenix the the held-for-sale expected in XXXX accretion
Turning view. now consolidated the to
adjusted to guidance compared growth XX% and increased revenue XX% assumes X% fiscal XXXX. to operating Our profit to growth XX%
remains And the unchanged. made initiative good our to million flexibility. earnings of we employee Xth savings we of increase America savings North to savings range fully of actions, These in expect million progress segments. of adjusted the approximately of to XX% annual We've And our now to million space effective half will based rate Fiscal against this initiative. $XXX of anticipate to expenses earlier efficiencies to corporate benefits when XXXX, all we $XXX realization $XX Our guidance rationalize with be On resulting million support $XX annual on XX% call, full-year May expense from implemented. outlined across tax and office to $XX in an million. second in the in of operating realized this progress, million these $XX
cash flow capital turn deployment. now and to Let me
$X.X $X.X We to expect in flow of of in billion fiscal is which free net cash acquisitions XXXX, expenses. approximately software property capitalized
flexibility and historically to approach, a year. our of to repurchases. for fourth allocation remaining strong our in shareholders flows services, returning quarter cash our cash long-term flow dividend strategies through positioning This oncology majority the execute investing business the committed of reminder, growth, As of generate financial fiscal generation our we capital the balanced a while and share to in capital biopharma our provides
Our including today. XXXX encouraged momentum outlook we grade year. positions in first half U.S. financial flexibility. our government, closing, partnership the priority with strong our updated rating underpins our The deliver the fiscal of here performance across in provided the business, the fiscal us investment by credit In to are a our remains
the Finally, at strategies Day the call we're time. looking strength December I'll And Xth. questions. our your now the your on forward businesses to our for of providing over to you upcoming turn additional and on details Investor Operator Thank our for
